144 related articles for article (PubMed ID: 11466370)
1. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
[TBL] [Abstract][Full Text] [Related]
2. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
Zahedi R; Wisnieski J; Davis AE
J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
[TBL] [Abstract][Full Text] [Related]
3. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein.
Zahedi R; Bissler JJ; Davis AE; Andreadis C; Wisnieski JJ
J Clin Invest; 1995 Mar; 95(3):1299-305. PubMed ID: 7883978
[TBL] [Abstract][Full Text] [Related]
4. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
5. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
[TBL] [Abstract][Full Text] [Related]
6. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sulikowski T; Bauer BA; Patston PA
Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex.
Luo C; Thielens NM; Gagnon J; Gal P; Sarvari M; Tseng Y; Tosi M; Zavodszky P; Arlaud GJ; Schumaker VN
Biochemistry; 1992 May; 31(17):4254-62. PubMed ID: 1533159
[TBL] [Abstract][Full Text] [Related]
8. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
[TBL] [Abstract][Full Text] [Related]
9. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
Eldering E; Huijbregts CC; Nuijens JH; Hack CE
Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
[No Abstract] [Full Text] [Related]
10. Functional analysis of the serpin domain of C1 inhibitor.
Coutinho M; Aulak KS; Davis AE
J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
[TBL] [Abstract][Full Text] [Related]
11. Identification of the C1q-binding Sites of Human C1r and C1s: a refined three-dimensional model of the C1 complex of complement.
Bally I; Rossi V; Lunardi T; Thielens NM; Gaboriaud C; Arlaud GJ
J Biol Chem; 2009 Jul; 284(29):19340-8. PubMed ID: 19473974
[TBL] [Abstract][Full Text] [Related]
12. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
[TBL] [Abstract][Full Text] [Related]
13. Expression of functional human C1 inhibitor in COS cells.
Eldering E; Nuijens JH; Hack CE
J Biol Chem; 1988 Aug; 263(24):11776-9. PubMed ID: 2841334
[TBL] [Abstract][Full Text] [Related]
14. Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251.
Zahedi R; Aulak KS; Eldering E; Davis AE
J Biol Chem; 1996 Sep; 271(39):24307-12. PubMed ID: 8798678
[TBL] [Abstract][Full Text] [Related]
15. Characterization of recombinant C1 inhibitor P1 variants.
Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
[TBL] [Abstract][Full Text] [Related]
16. The structure and function of the first component of complement: genetic engineering approach (a review).
Gál P; Cseh S; Schumaker VN; Závodszky P
Acta Microbiol Immunol Hung; 1994; 41(4):361-80. PubMed ID: 7866721
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s.
Sim RB; Arlaud GJ; Colomb MG
Biochim Biophys Acta; 1980 Apr; 612(2):433-49. PubMed ID: 6245704
[No Abstract] [Full Text] [Related]
18. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
[TBL] [Abstract][Full Text] [Related]
19. Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor.
Bos IG; Lubbers YT; Eldering E; Abrahams JP; Hack CE
Biochim Biophys Acta; 2004 Jun; 1699(1-2):139-44. PubMed ID: 15158721
[TBL] [Abstract][Full Text] [Related]
20. Activation of human complement serine-proteinase C1r is down-regulated by a Ca(2+)-dependent intramolecular control that is released in the C1 complex through a signal transmitted by C1q.
Thielens NM; Illy C; Bally IM; Arlaud GJ
Biochem J; 1994 Jul; 301 ( Pt 2)(Pt 2):509-16. PubMed ID: 8042996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
